SAR407899 + Placebo + Adenosine + Regadenoson + 13N-ammonia + 82Rubidium
Phase 2Terminated 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Microvascular Coronary Artery Disease
Conditions
Microvascular Coronary Artery Disease
Trial Timeline
Oct 12, 2017 → Jul 23, 2018
NCT ID
NCT03236311About SAR407899 + Placebo + Adenosine + Regadenoson + 13N-ammonia + 82Rubidium
SAR407899 + Placebo + Adenosine + Regadenoson + 13N-ammonia + 82Rubidium is a phase 2 stage product being developed by Sanofi for Microvascular Coronary Artery Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT03236311. Target conditions include Microvascular Coronary Artery Disease.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03236311 | Phase 2 | Terminated |
Competing Products
7 competing products in Microvascular Coronary Artery Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Zibotentan + Placebo oral tablet | AstraZeneca | Phase 2 | 52 |
| Lercanidipine + Valsartan + Nicorandil + Doxazosin + Moxonidin + Pindolol + Amiloride, hydrochlorothiazide | Novartis | Pre-clinical | 23 |
| Ranolazine + Placebo | Gilead Sciences | Approved | 84 |
| Ranolazine + Placebo | Gilead Sciences | Phase 2 | 51 |
| Temanogrel + Placebo | Pfizer | Phase 2 | 51 |
| SAR247799 + Placebo + Sildenafil + Acetylcholine | Sanofi | Phase 1 | 32 |
| Felzartamab + Placebo | Biogen | Phase 2 | 49 |